[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diagnose-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diagnose-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100626755","ai-powered-precision-decision-making-for-pancreatic-diseases-100626755",false,"NCT07439757","AI-Powered Precision Decision-Making for Pancreatic Diseases","A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT","Inclusion Criteria:\n\n* Clinically suspected pancreatic disease.\n* Scheduled to undergo contrast-enhanced CT.\n* Signed informed consent form indicating agreement to participate.\n\nExclusion Criteria:\n\n* History of pancreatic surgery.\n* Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal\u002Fhepatic dysfunction.\n* Suboptimal image quality affecting diagnosis.\n* Concurrent participation in another interventional clinical trial.\n* Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.","ALL","18 Years","80 Years",{"count":20,"type":21},2000,"ESTIMATED","1 Year","OBSERVATIONAL","This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery\u002Ftreatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.",[26,27,28,29,30,31,32],"Pancreatic Cancer","Diagnose Disease","IPMN, Pancreatic","Pancreatic Cystic Lesions","Chronic Pancreatitis","Pancreatic Neuroendocrine Tumor","Acute Pancreatitis (AP)",[34],"Artificial Intelligence (AI), Deep Learning, Contrast-Enhanced CT, Multicenter Clinical Trial, Real-World Study","RECRUITING","2026-02-23",{"date":38,"type":39},"2026-02-27","ACTUAL",{"date":41,"type":21},"2026-03-01",{"date":43,"type":21},"2029-10-31",{"name":45,"class":46},"Changhai Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100399037","early-diagnosis-of-upper-digestive-tract-disease-100399037","NCT04475952","Early Diagnosis of Upper Digestive Tract Disease","E-DIGEST","Inclusion Criteria:\n\n* Any patient who:\n\n  * is ≥ 18 years old and below 90 years of age, AND:\n  * is undergoing endoscopy as part of their routine clinical care, OR:\n  * is undergoing surgical resection of orodigestive tract disease as part of their routine clinical care, OR:\n  * is undergoing treatment of orodigestive tract disease as part of their routine clinical care\n\nExclusion Criteria:\n\n* Any patient who:\n\n  * Lacks capacity or is unable to provide informed consent.\n  * Any patient below 18 years of age or over 90 years of age.",true,"90 Years",{"count":58,"type":21},180,"Upper digestive tract cancer (UDC) is a major disease burden worldwide encompassing all cancers involving the digestive tract (from oral cavity to duodenum). A majority of patients presenting with this disease are diagnosed late and have poor overall survival rates (\\\u003C20%). NICE referral guidelines for diagnostic endoscopy are usually associated with late disease. Exhaled breath testing is a non-invasive and acceptable technology utilising mass spectrometry (MS) which has shown promise at diagnosing cancer at an early stage.\n\nPrevious research has shown that products formed as a result of metabolism can be measured in breath and saliva (biomarkers). This has the ability to accurately identify patients with upper gastrointestinal (UGI) cancers from breath. Our initial pilot data has demonstrated that changes in the breakdown of metabolites release volatile organic compounds (VOC) which can be measured with MS. This data is supported by other patient studies. However no previous study has been performed utilising a non-invasive technique with breath and saliva. Thus the aim of this study is to identify VOCs present in patients with this disease.\n\nIn this multi-centre study the investigators want to overcome the limitations of previous work by utilising non-invasive samples (breath, saliva and urine) in patients in multiple sites. The investigators aim to conduct a study in patients with UDC and those without. The investigators hope that the results of this study will provide evidence for large scale analysis of patients with this disease, demonstrate the feasibility of this technique and move this valuable test forward into mainstream medical practice. The major advantage of this test is that it is easy to undertake and painless for the patient. This study of products in breath, saliva and urine will be useful for detecting UDC to allow treatment at an early stage, improving overall survival.",[61,62,63,27],"Squamous Cell Carcinoma","Breath Test","Digestive System Disease","2025-02-07",{"date":66,"type":39},"2025-02-10",{"date":68,"type":39},"2019-09-13",{"date":70,"type":21},"2025-09-13",{"name":72,"class":46},"Imperial College London",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":55,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":82,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":47},"100555280","assessment-of-pancreatic-physiological-and-pathological-characteristics-based-on-spectral-ct-100555280","NCT06510036","Assessment of Pancreatic Physiological and Pathological Characteristics Based on Spectral CT","Assessment of Pancreatic Physiological and Pathological Characteristics Based on Spectral CT Feature Parameters: A Related Study","Inclusion Criteria:\n\n1.Since March 2024, I have been visiting our hospital for various reasons and have undergone CT scans involving the pancreas (using energy spectrum CT)\n\nExclusion Criteria:\n\n1. Previous pancreatic surgery with incomplete pancreatic tissue.\n2. Severe systemic diseases that result in severe organ dysfunction\n3. Excessive pancreatic atrophy or other reasons cannot accurately delineate ROI",{"count":81,"type":21},1500,"3 Years","Patients who visited our hospital for various reasons from January 2024, underwent CT scans involving the pancreas, and were eligible for spectral post-processing reconstruction were included in the study. This research collected spectral CT data related to the pancreas at different phases, as well as physiological and pathological states for these patients. Quantitative analysis was conducted on post-processed data under different physiological and pathological states, including parameters such as pancreatic iodine uptake features, attenuation interval slopes, and extracellular volume size. In conjunction with general patient status, biochemical tests, and postoperative pathological results, the study aimed to identify correlations between parameters, develop models, and conduct research by comparing traditional CT data, which could be matched with spectral CT from the PACS database since its establishment.",[27],"2024-12-02",{"date":87,"type":39},"2024-12-04",{"date":89,"type":39},"2021-01-21",{"date":91,"type":21},"2028-06-21",{"name":93,"class":46},"Yu Shi"]